116 related articles for article (PubMed ID: 36054337)
1. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Berner F; Bomze D; Lichtensteiger C; Walter V; Niederer R; Hasan Ali O; Wyss N; Bauer J; Freudenmann LK; Marcu A; Wolfschmitt EM; Haen S; Gross T; Abdou MT; Diem S; Knöpfli S; Sinnberg T; Hofmeister K; Cheng HW; Toma M; Klümper N; Purde MT; Pop OT; Jochum AK; Pascolo S; Joerger M; Früh M; Jochum W; Rammensee HG; Läubli H; Hölzel M; Neefjes J; Walz J; Flatz L
Sci Immunol; 2022 Sep; 7(75):eabn9644. PubMed ID: 36054337
[TBL] [Abstract][Full Text] [Related]
2. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
[TBL] [Abstract][Full Text] [Related]
3. Lack of CD8
Horton BL; Morgan DM; Momin N; Zagorulya M; Torres-Mejia E; Bhandarkar V; Wittrup KD; Love JC; Spranger S
Sci Immunol; 2021 Oct; 6(64):eabi8800. PubMed ID: 34714687
[TBL] [Abstract][Full Text] [Related]
4. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
[TBL] [Abstract][Full Text] [Related]
6. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Berner F; Niederer R; Luimstra JJ; Pop OT; Jochum AK; Purde MT; Hasan Ali O; Bomze D; Bauer J; Freudenmann LK; Marcu A; Wolfschmitt EM; Haen S; Gross T; Dubbelaar ML; Abdou MT; Baumgaertner P; Appenzeller C; Cicin-Sain C; Lenz T; Speiser DE; Ludewig B; Driessen C; Jörger M; Früh M; Jochum W; Cozzio A; Rammensee HG; Walz J; Neefjes J; Flatz L
Oncoimmunology; 2021; 10(1):2006893. PubMed ID: 34858733
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8
Watson RA; Tong O; Cooper R; Taylor CA; Sharma PK; de Los Aires AV; Mahé EA; Ruffieux H; Nassiri I; Middleton MR; Fairfax BP
Sci Immunol; 2021 Oct; 6(64):eabj8825. PubMed ID: 34597125
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
9. The ectonucleotidase CD39 identifies tumor-reactive CD8
Chow A; Uddin FZ; Liu M; Dobrin A; Nabet BY; Mangarin L; Lavin Y; Rizvi H; Tischfield SE; Quintanal-Villalonga A; Chan JM; Shah N; Allaj V; Manoj P; Mattar M; Meneses M; Landau R; Ward M; Kulick A; Kwong C; Wierzbicki M; Yavner J; Egger J; Chavan SS; Farillas A; Holland A; Sridhar H; Ciampricotti M; Hirschhorn D; Guan X; Richards AL; Heller G; Mansilla-Soto J; Sadelain M; Klebanoff CA; Hellmann MD; Sen T; de Stanchina E; Wolchok JD; Merghoub T; Rudin CM
Immunity; 2023 Jan; 56(1):93-106.e6. PubMed ID: 36574773
[TBL] [Abstract][Full Text] [Related]
10. Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer.
Lau D; Khare S; Stein MM; Jain P; Gao Y; BenTaieb A; Rand TA; Salahudeen AA; Khan AA
Nat Commun; 2022 Jul; 13(1):4053. PubMed ID: 35831288
[TBL] [Abstract][Full Text] [Related]
11. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.
Pai JA; Hellmann MD; Sauter JL; Mattar M; Rizvi H; Woo HJ; Shah N; Nguyen EM; Uddin FZ; Quintanal-Villalonga A; Chan JM; Manoj P; Allaj V; Baine MK; Bhanot UK; Jain M; Linkov I; Meng F; Brown D; Chaft JE; Plodkowski AJ; Gigoux M; Won HH; Sen T; Wells DK; Donoghue MTA; de Stanchina E; Wolchok JD; Loomis B; Merghoub T; Rudin CM; Chow A; Satpathy AT
Cancer Cell; 2023 Apr; 41(4):776-790.e7. PubMed ID: 37001526
[TBL] [Abstract][Full Text] [Related]
12. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.
Correale P; Saladino RE; Giannarelli D; Giannicola R; Agostino R; Staropoli N; Strangio A; Del Giudice T; Nardone V; Altomonte M; Pastina P; Tini P; Falzea AC; Imbesi N; Arcati V; Romeo G; Caracciolo D; Luce A; Caraglia M; Giordano A; Pirtoli L; Necas A; Amler E; Barbieri V; Tassone P; Tagliaferri P
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554614
[TBL] [Abstract][Full Text] [Related]
13. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
14. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.
Sato Y; Bolzenius JK; Eteleeb AM; Su X; Maher CA; Sehn JK; Arora VK
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518683
[TBL] [Abstract][Full Text] [Related]
15. Antigen dominance hierarchies shape TCF1
Burger ML; Cruz AM; Crossland GE; Gaglia G; Ritch CC; Blatt SE; Bhutkar A; Canner D; Kienka T; Tavana SZ; Barandiaran AL; Garmilla A; Schenkel JM; Hillman M; de Los Rios Kobara I; Li A; Jaeger AM; Hwang WL; Westcott PMK; Manos MP; Holovatska MM; Hodi FS; Regev A; Santagata S; Jacks T
Cell; 2021 Sep; 184(19):4996-5014.e26. PubMed ID: 34534464
[TBL] [Abstract][Full Text] [Related]
16. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
17. Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade.
Chen S; McMiller TL; Soni A; Succaria F; Sidhom JW; Cappelli LC; Casciola-Rosen LA; Morales IR; Sankaran P; Berger AE; Deutsch JS; Zhu QC; Anders RA; Hooper JE; Pardoll DM; Lipson EJ; Taube JM; Topalian SL
J Transl Med; 2024 Mar; 22(1):241. PubMed ID: 38443917
[TBL] [Abstract][Full Text] [Related]
18. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
19. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
[TBL] [Abstract][Full Text] [Related]
20. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
